iBio (IBIO) Registration Filing summary

Company overview and business model

• Preclinical stage biotechnology company focused on AI-driven discovery of precision antibodies for cardiometabolic and obesity indications.

• Utilizes an integrated AI Drug Discovery Platform to rapidly identify and optimize biologics targeting unmet needs in obesity and related diseases.

• Pipeline includes multiple preclinical candidates, with IBIO-610 (Activin E inhibitor) as the lead, aiming for first human trials in early 2027.

• Pursues strategic collaborations and out-licensing in areas such as immunology, pain, and vaccines to leverage its AI platform beyond core focus.

Financial performance and metrics

• Raised approximately $26 million in gross proceeds from a private placement in January 2026, before agent commissions and offering expenses.

Use of proceeds and capital allocation

• Net proceeds from the private placement are allocated to advance preclinical cardiometabolic programs (including IBIO-610, IBIO-600, and myostatin/activin A bispecifics) through key milestones.

• Remaining funds to support other pipeline assets, working capital, and general corporate purposes.